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In all, 31 renal cell carcinomas (RCCs) were examined for expression of the potential tumour suppressor LRIG1 (formerly Lig-1) and
the epidermal growth factor receptor (EGFR). Eight matched samples of uninvolved kidney cortex were also evaluated. Gene
expression was examined by quantitative real-time RT–PCR. In the eight matched sample pairs (uninvolved kidney cortex and
tumour), protein expression was examined by immunohistochemistry. Conventional (clear cell) tumours showed an expected
upregulation of EGFR. LRIG1 expression was generally downregulated in conventional and papillary RCC but not in chromophobic
RCC. The ratio between EGFR and LRIG1 was more than 2.5-fold higher in the eight tumours compared with matched uninvolved
kidney cortex and was at least two-fold higher than the mean normal ratio in 21 of 31 samples analysed. The observed
downregulation of LRIG1 and increased EGFR/LRIG1 ratios are consistent with LRIG1 being a suppressor of oncogenesis in RCC by
counteracting the tumour-promoting properties of EGFR. Further studies are justified to elucidate the explicit role of LRIG1 in the
oncogenesis of RCC.
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Renal cell carcinoma (RCC) represents 2–3% of all cancer. There
are distinct subclasses of RCC, differing in histopathological
appearance and genetic alterations. The most common accounting
for approximately 70% of these tumours are conventional (clear
cell) RCC. Papillary RCC accounts for 10–15%, chromophobe RCC
for about 5% and collecting duct carcinoma for less than 1%
(Kovacs et al, 1997; Sto ¨rkel et al, 1997). Despite many efforts to
develop effective therapies, including immunotherapy, hormone
manipulation and chemotherapy, the survival of advanced RCC
still remains poor (Henriksson et al, 1998; Motzer and Russo,
2000). So far, the knowledge of the different histopathological
entities of RCC has not led to differences in the management of
RCC. Previous studies have shown epidermal growth factor
receptor (EGFR) overexpression in RCC, but its prognostic
significance is controversial (Lager et al, 1994; Ljungberg et al,
1994; Yoshida and Tosaka, 1994; Hofmockel et al, 1997). The EGFR
ligands EGF and TGFa are also frequently overexpressed in RCC.
TGFa has a low expression in normal kidney and may be involved
in an autocrine loop with EGFR in RCC (Mydlo et al, 1989). This is
particularly interesting since therapies targeting EGFR have shown
interesting results in the treatment of other cancers (Baselga and
Averbuch, 2000; Mendelsohn and Baselga, 2000). Human LRIG1
(formerly LIG1) has recently been cloned and characterised
(Nilsson et al, 2001). LRIG1 is a transmembrane cell surface
protein with structural similarities to the Drosophila (fruit fly) cell
surface protein Kekkon-1 that participates in an EGF-driven
negative feedback loop (Ghiglione et al, 1999). LRIG1 is localised
to chromosome 3p14 (Nilsson et al, 2001), a region often deleted in
conventional RCC (van den Berg and Buys, 1997). Owing to its
interesting chromosomal localisation and its potentially EGFR-
inhibiting qualities, we found it of interest to examine the
expression of LRIG1 in RCC and to evaluate its relationship with
the expression of EGFR, in RCC and in normal kidney tissue from
the same patients.
MATERIALS AND METHODS
Patients
Specimens and clinical data were obtained from 31 patients with
RCC who underwent nephrectomy at the Umea ˚ University
Hospital between 1986 and 1998 (Table 1), in accordance with
the regulations approved by the ethical committee of the Umea ˚
University Hospital. Of these tumours, 18 were conventional (clear
cell), 10 papillary and three chromophobe RCCs. In eight (five with
conventional and three with papillary RCC) of the patients, we
obtained matched specimen of grossly non-neoplastic kidney
cortex tissue.
Quantitative RNA analysis
RNA was prepared from tissue samples by mechanical disruption
in TRIzol reagent (Gibco-BRL, Rockville, MD, USA), followed by Received 5 February 2003; accepted 18 June 2003
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ychloroform extraction and alcohol precipitation according to the
manufacturer’s instructions as described (Nilsson et al, 2001).
Real-time quantitative reverse transcription (RT)–PCR was
performed as described (Nilsson et al, 2001) using an iCycler
(Bio-Rad, Hercules, CA, USA). Primers and probes (Table 2) were
synthesised by Scandinavian Gene Synthesis AB (Ko ¨ping, Sweden).
RNA samples were run in triplicate using 20ng of RNA per
reaction. Relative quantification was performed by comparing the
threshold cycle values (Ct) for the samples, with standard curves
generated with cloned cDNAs of respective genes (Nilsson et al,
2001). To correct for differences in RNA quality and quantity, the
apparent levels of 18S rRNA were used to normalise the EGFR and
LRIG1 values in respective RNA samples.
Immunohistochemistry
From blocks of formalin-fixed and paraffin-embedded tissues,
5mm-thick sections were cut and mounted with samples of normal
and tumour tissue on the same slide. The sections were
deparaffinised by standard methods. Endogenous peroxidase
activity was blocked with 3% peroxidase in methanol for 20min
and washed in PBS 3 5min. The samples were merged in 0.01 M
citrate buffer pH 7.3 and treated with microwaves (1400W
1 5min LRIG1 and 720W 1 5minþ500W 2 5min for
EGFR). Samples, preincubated with 10% goat serum for 30min
to block unspecific binding, were incubated with primary
antibodies (LRIG1, a polyclonal rabbit antibody, diluted 1:500
and for EGFR a polyclonal rabbit antibody, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA diluted 1:100, overnight). Sections
were washed in PBS 3 5min, before application of the
biotinylated secondary goat antibody (Vector Laboratories,
Burlingame, CA, USA) diluted 1:200 for 40 and 30min,
respectively. Thereafter, specimens were washed 3 5min in PBS
and incubated with the DAB substrate kit (Vector Laboratories),
according to the manufacturer’s instructions. The sections were
rinsed in water, counterstained with Mayer staining, again rinsed
in water and mounted. Negative controls with a primary polyclonal
rabbit antibody against GFP, a non-human protein, showed no
staining. All stainings with respective antibodies were conducted at
the same time, under the same conditions. The intensity of the
staining of the tumour was compared with that of the correspond-
ing normal tissue and graded as follows: 0¼no staining, þ¼less
staining than the corresponding kidney cortex from the same
patient, þþ¼equal staining to the kidney cortex tissue,
þþþ¼more staining than the kidney cortex.
RESULTS
Quantitative RNA analysis
In order to examine the mRNA expression of EGFR and LRIG1 in
RCC, 31 tumour RNA samples and corresponding kidney tissue in
eight of these patients were analysed by quantitative RT–PCR.
Expression of the EGFR was observed in all analysed samples. The
expression of EGFR was elevated in most of the tumours compared
to the mean in the kidney cortex (Figure 1A) and was markedly
increased in six of the eight tumours for which the corresponding
kidney cortex was available for comparison. One conventional
RCC with very high EGFR expression in the normal tissue and one
papillary tumour did not show any significant increase in the
tumour tissue (Figure 1B). LRIG1 expression appeared down-
regulated in the majority of tumours (Figure 1C) and was
decreased in six of eight tumours compared with kidney cortex
tissue from the same patient. One conventional and one papillary
RCC showed unchanged or increased LRIG1 levels compared to
normal kidney tissue (Figure 1D). When relating the LRIG1 and
EGFR levels in tumour and kidney to each other, the ratio of
EGFR/LRIG1 appeared high, especially in conventional RCCs
(Figure 1E). It was increased at least 2.5-fold, in eight out of eight
tumours compared to corresponding kidney cortex tissue
(Figure 1F), and when comparing the ratio in all tumours with
the mean normal value, 21 out of 31 tumours showed at least a
two-fold increased ratio.
Immunohistochemistry
All normal tissue and tumours stained strongly for EGFR (Table 3,
Figure 2). EGFR in the kidney cortex displayed a pattern with
staining of tubular structures, distal tubules staining slightly more
intensely than proximal tubules. No staining was seen in
connective tissue and in the glomeruli. Tumour cells were
homogeneously stained (Figure 2). The staining pattern of LRIG1
in the kidney cortex was very similar to that of EGFR with a most
prominent staining in the tubuli (Figure 2), few scattered LRIG1-
positive cells were seen in the glomeruli. In tumours, the intensity
of LRIG1 staining was generally less pronounced than in the
kidney cortex tissue. Some tumours had scattered clusters of
positive cells (Table 3).
Table 1 Characterisation of patients and tumours included in the study
Total no of patients 31
Sex (male/female) 17/14
Age (years) median (range) 64 (36–85)
Tumour diameter, median (range) 80 (30–250)
TNM stage 1 7
TNM stage 2 5
TNM stage 3 10
TNM stage 4 9
Tumour grade 2 5
Tumour grade 3 21
Tumour grade 4 5
Known metastasis at the time of nephrectomy 9
Survival time (months), median (range) 44 (1–139)
Table 2 Oligonucleotide primer and probe sequences for real-time quantitative RT-PCR
Templates Oligonucleotides Sequences PCR product
size (bp)
EGFR Forward primer 50-TCCCTCAGCCACCCATATGTAC-30 125
Reverse primer 50-GTCTCGGGCCATTTTGGAGAATCC-30
Probe 50-
afATCACC
bQCACGGAACTTTGGGCGACTATCTGCGTC-30
LRIG1 Forward primer 50-GGTGAGCCTGGCCTTATGTGAATA-30 108
Reverse primer 50-CACCACCATCCTGCACCTCC-30
Probe 50-
afACACAT
bQGGTAGCGGCCCTCGTGCCCG-30
18S Forward primer 50-CGGCGACGACCCATTCGAAC-30 99
Reverse primer 50-GAATCGAACCCTGATTCCCCGTC-30
Probe 50-
afCCTATCAAC
bQTTCGATGGTAGTCGCCGTGCC-30
Note.
af denotes a 50-conjugated fluorescein and
bQ denotes a T with a conjugated Dark Quencher molecule.
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Figure 1 Expression of EGFR and LRIG1 mRNA in RCC and normal kidney. Total RNA was prepared from respective tumour and normal tissues and
analysed for EGFR and LRIG1 mRNA and 18S rRNA by quantitative real-time PCR. EGFR and LRIG1 levels were normalised to the 18S rRNA levels in the
respective samples. (A) EGFR mRNA expression in 31 RCC patients divided by tumour subgroups. (B) EGFR mRNA expression in eight RCC tumours and
matching normal kidney tissue from the same patients. (C) LRIG1 mRNA expression in 31 RCC patients divided by tumour subgroups. (D) LRIG1mRNA
expression in eight RCC tumours and matching normal kidney tissue from the same patients. (E) The EGFR/LRIG1 expression ratio in 31 RCC patients
divided by tumour subgroups. (F) The EGFR/LRIG1 expression ratio in eight RCC tumours and matching normal kidney tissue from the same patients.
Samples C.1–18 were conventional RCCs, samples Ch.1–3 were chromophobic RCCs and samples P.1–10 were papillary RCCs. In (A), (C) and (E), the
mean of normal tissues in (B), (D) and (F), respectively, and an extra normal sample (from a patient with a non-RCC tumour) are displayed with the
standard deviation indicated by error bars.
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Even though the number of patients in this study was limited to 31
patients, we wanted to investigate if any correlations of interest
could be seen between the expression of LRIG1 and EGFR and
clinical parameters. The most substantial finding was the relation
between tumour expression of LRIG1 mRNA and tumour grade
(Figure 3A). The grade 4 tumours expressed lower levels of LRIG1
than seen in grade 2 and 3 tumours, but the groups did not differ
significantly (P-value 0.0881, Kruskal – Wallis). When divided into
groups of high- and low-expressing tumours (median used as
cutoff level), a Kaplan – Meier analysis showed a tendency for a
nonsignificant survival benefit for patients with high LRIG1-
expressing tumours (Figure 3B).
DISCUSSION
In this study, using quantitative PCR and immunohistochemistry,
it was shown that the expression of LRIG1 was decreased and the
ratio of EGFR/LRIG1 was increased in tumours vs normal tissue.
This novel finding in a human tumour specimen lends support to
the suggestion that LRIG1 acts as a tumour suppressor and
negative regulator of EGFR (Nilsson et al, 2001; Hedman et al,
2002). EGFR mediates signals that stimulate proliferation, migra-
tion and metastasis in many types of tumours, including RCC
(Mydlo et al, 1989; Ljungberg et al, 1994; Yarden, 2001). The
localisation of LRIG1 at 3p14.3 is of particular interest since this
region is often lost in RCC, particularly in conventional RCC (van
den Berg and Buys, 1997). The region of 3p12–14 thus seems
important in the search for tumour suppressor genes in RCC. This
region has displayed a tumour-suppressing effect when reintro-
duced into RCC cell lines (Sanchez et al, 1994). Earlier, two other
possible tumour suppressor genes have been suggested in this
area, one at 3p12 and FIT at 3p14.2 (Lovell et al, 1999; Velickovic
et al, 1999). We now suggest that LRIG1 also should be considered
as a possible tumour suppressor gene in the genomic region
3p12–14.
Conventional RCC obviously displayed lower expressions of
LRIG1 than the kidney cortex, six of eight matched tumour
samples had decreased expression and one was unchanged
compared to kidney cortex tissue. In contrast, a relatively high
expression of LRIG1 was seen in all three chromophobe RCC
analysed. When we compared the ratio between EGFR and LRIG1
mRNA, an interesting relationship was observed. The EGFR/LRIG1
ratio was increased at least 2.5-fold in all tumours matched with
the corresponding kidney cortex. These observations were
seemingly supported by the immunohistochemical analysis. This
relationship was not seen when we compared LRIG1 to the other
members of the EGFR family (unpublished observations). The
Table 3 Immunohistochemical staining intensity of EGFR and LRIG1 in
tumours compared with normal tissue from the same patients
Patient Type of RCC EGFR staining LRIG1 staining
C.2 Conventional +++ ++
C.9 Conventional ++ +
a
C.11 Conventional +++ 0
C.15 Conventional ++ +
C.17 Conventional + +
P.6 Papillary +++ +
a
P.8 Papillary +++ ++
P.9 Papillary ++ +
The intensity was graded 0¼no staining, +¼less staining than the kidney cortex
from the same patient, ++¼equal staining as kidney cortex, +++¼more staining
than the kidney cortex.
aExhibited scattered clusters of positive cells.
Figure 2 Immunohistochemical staining for EGFR and LRIG1.Tissue
sections were stained using indicated antibodies and HRP-conjugated
secondary antibodies and counter-stained with Mayer’s solution. Samples
were obtained from the patient referred to as C.9 and the respective
scorings are indicated in parentheses. (A) EGFR in normal kidney. (B)
EGFR in conventional RCC (þþ). (C) LRG1 in normal kidney. (D) LRIG1
in conventional RCC (þ). Original magnification  200.
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Figure 3 LRIG1 expression in relation to histological grade and survival.
LRIG1 mRNA expression levels were quantified using real-time RT–PCR,
and normalised to the 18s rRNA levels in the respective samples. (A)
Relationship between tumour grade and the expression of LRIG1 mRNA.
A tendency of lower expression in grade 4 tumours is seen. Differences
between tumours of different grades were not statistically significant
(P-value of 0.0881, Kruskal–Wallis). (B) Kaplan–Meier survival curves for
31 patients with tumours expressing above and below median LRIG1
mRNA levels. Differences between the curves were not statistically
significant (P-value¼0.1499).
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suggestion that LRIG1 functions as a tumour suppressor and
inhibitor of EGFR in humans. Interestingly, we have recently
detected the downregulation of LRIG1 in some tumour cell lines of
different origin (Hedman et al, 2002). Our data demonstrated an
apparent difference in the expression of LRIG1 in chromophobe
RCC, which appeared to express more LRIG1 than conventional or
papillary RCC. This is consistent with the earlier observation that
chromophobe RCCs display distinct genetic alterations (Kovacs
et al, 1997) and expression profiles distinct from conventional
RCCs (Young et al, 2001). These findings taken together highlight
that the different subgroups of RCC should be regarded as
different diseases. Although the numbers of tumours analysed
were limited, the observations that the tumours of grade 4 seemed
to express less LRIG1 than tumours of lower grades and that a
small survival benefit for patients with tumours with high
expression of LRIG1 were indicated; this might lend further
support to the fact that LRIG1 participates in the oncogenesis of
RCC.
In conclusion, the underexpression of LRIG1 and the increase in
EGFR/LRIG1 ratios found in RCC compared to the kidney cortex
indicate that LRIG1 might be a tumour suppressor that counteracts
the tumour-promoting function of EGFR. Thus, further studies
evaluating larger tumour materials and addressing the molecular
function of LRIG1 are warranted.
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